NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kinaset Therapeutics

Kinaset Therapeutics

Private
Medfield, MassachusettsHealthcare & Life Scienceshttps://www.kinasettherapeutics.com/

Last Round

Series B

Jan 10, 2026

Total Funding Raised

$171.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kinaset Therapeutics is a biopharmaceutical company that develops inhaled therapeutics for serious respiratory diseases, including severe asthma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalinhaled therapyrespiratory diseaseasthma treatmentclinical-stage biotechdrug developmentclinical trialssmall-molecule therapeuticsairway diseasebiotech pipelinedrug licensingpharma R&Dbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kinaset Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Kinaset Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kinaset Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 10, 2026
Series A ExtensionJul 18, 2022
Series ANov 30, 2020

Key People

Founding team and executive leadership

Roger Heerman

Chief Business Officer And Co-Founder

Founding Team

Kinaset Therapeutics Investors

Notable investors and investment history

Kinaset Therapeutics investors
InvestorRounds
RA Capital ManagementSeries B
Sixty Degree CapitalSeries B
EQT Life SciencesSeries B
SV Health InvestorsSeries A Extension
GimvSeries B, Series A, Series A Extension
5AM VenturesSeries B, Series A Extension, Series A
AccompliceSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    Daniela Begolo from EQT Life Sciences joins the board.

  • Jan 10, 2026

    Peter B. Silverman joins the board, formerly of Forge Life Science Partners.

Kinaset Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kinaset Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kinaset Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMedfield, Massachusetts
Employee Range15
Year Founded2020
Last FundingJan 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.